Illumina, Inc. (ILMN) Stock

About Illumina, Inc.

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Illumina, Inc. is led by CEO Jacob Thaysen, employs 8,970 people, headquartered in San Diego, US, publicly traded since 2000.

Illumina, Inc. (ILMN) stock trades at $189.61 with a market capitalization of $28.69B. The stock is valued at a price-to-earnings (P/E) ratio of 26.54, price-to-book of 8.33, price-to-sales of 5.66. Over the past 52 weeks the stock has ranged between $77.50 and $197.83, and currently trades 4.2% below its 52-week high.

On profitability, Illumina, Inc. generates a return on equity (ROE) of 33.82% — well above the market average, a sign of a high-quality business, return on capital employed of 31.73%, an operating margin of 18.33%, a net profit margin of 19.43%.

In its most recent fiscal year, Illumina, Inc. reported annual revenue of $4.3B, net profit of $850.0M, revenue has compounded at 6.0% a year over the last five years, profit at 5.3% a year.

The balance sheet shows a debt-to-equity ratio of 0.95, a current ratio of 1.75, total assets of $6.6B, $1.4B in cash and equivalents.

ILMN has an average daily trading volume of 1,876,495 shares, a beta of 1.49 (more volatile than the overall market).

Official website: www.illumina.com